JP2015520768A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015520768A5 JP2015520768A5 JP2015514149A JP2015514149A JP2015520768A5 JP 2015520768 A5 JP2015520768 A5 JP 2015520768A5 JP 2015514149 A JP2015514149 A JP 2015514149A JP 2015514149 A JP2015514149 A JP 2015514149A JP 2015520768 A5 JP2015520768 A5 JP 2015520768A5
- Authority
- JP
- Japan
- Prior art keywords
- fragment
- antibody
- composition
- ccl2
- ccl2 antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000012634 fragment Substances 0.000 claims description 51
- 239000000203 mixture Substances 0.000 claims description 29
- 206010039710 Scleroderma Diseases 0.000 claims description 21
- 210000002216 heart Anatomy 0.000 claims description 10
- 210000004072 lung Anatomy 0.000 claims description 10
- 210000003734 kidney Anatomy 0.000 claims description 6
- 210000004185 liver Anatomy 0.000 claims description 6
- 210000004204 blood vessel Anatomy 0.000 claims description 4
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 4
- 238000001990 intravenous administration Methods 0.000 claims description 4
- 210000002346 musculoskeletal system Anatomy 0.000 claims description 4
- 238000007911 parenteral administration Methods 0.000 claims description 4
- 210000003491 skin Anatomy 0.000 claims description 4
- 230000003442 weekly effect Effects 0.000 claims description 3
- 206010016654 Fibrosis Diseases 0.000 claims description 2
- 206010021143 Hypoxia Diseases 0.000 claims description 2
- 230000005779 cell damage Effects 0.000 claims description 2
- 208000037887 cell injury Diseases 0.000 claims description 2
- 230000002354 daily effect Effects 0.000 claims description 2
- 210000002889 endothelial cell Anatomy 0.000 claims description 2
- 230000003203 everyday effect Effects 0.000 claims description 2
- 230000004761 fibrosis Effects 0.000 claims description 2
- 230000007954 hypoxia Effects 0.000 claims description 2
- 230000008595 infiltration Effects 0.000 claims description 2
- 238000001764 infiltration Methods 0.000 claims description 2
- 210000005087 mononuclear cell Anatomy 0.000 claims description 2
- 238000007788 roughening Methods 0.000 claims description 2
- 238000007920 subcutaneous administration Methods 0.000 claims description 2
- 208000024891 symptom Diseases 0.000 claims description 2
- 230000000699 topical effect Effects 0.000 claims description 2
- 230000002792 vascular Effects 0.000 claims description 2
- 230000009278 visceral effect Effects 0.000 claims description 2
- 102100021943 C-C motif chemokine 2 Human genes 0.000 claims 1
- 201000003066 Diffuse Scleroderma Diseases 0.000 claims 1
- 101000897480 Homo sapiens C-C motif chemokine 2 Proteins 0.000 claims 1
- 206010042953 Systemic sclerosis Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 description 23
- 208000000185 Localized scleroderma Diseases 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261650149P | 2012-05-22 | 2012-05-22 | |
| US61/650,149 | 2012-05-22 | ||
| PCT/US2013/042196 WO2013177264A1 (en) | 2012-05-22 | 2013-05-22 | Anti-ccl2 antibodies for treatment of scleroderma |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017151434A Division JP2017193588A (ja) | 2012-05-22 | 2017-08-04 | 強皮症の処置用の抗−ｃｃｌ２抗体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015520768A JP2015520768A (ja) | 2015-07-23 |
| JP2015520768A5 true JP2015520768A5 (enExample) | 2016-06-30 |
Family
ID=49624311
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015514149A Pending JP2015520768A (ja) | 2012-05-22 | 2013-05-22 | 強皮症の処置用の抗−ｃｃｌ２抗体 |
| JP2017151434A Pending JP2017193588A (ja) | 2012-05-22 | 2017-08-04 | 強皮症の処置用の抗−ｃｃｌ２抗体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017151434A Pending JP2017193588A (ja) | 2012-05-22 | 2017-08-04 | 強皮症の処置用の抗−ｃｃｌ２抗体 |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US20150158942A1 (enExample) |
| EP (1) | EP2852411A4 (enExample) |
| JP (2) | JP2015520768A (enExample) |
| CN (2) | CN105854015A (enExample) |
| AU (2) | AU2013266340A1 (enExample) |
| BR (1) | BR112014029013A2 (enExample) |
| CA (1) | CA2874031A1 (enExample) |
| EA (1) | EA201491957A1 (enExample) |
| HK (2) | HK1208819A1 (enExample) |
| IN (1) | IN2014DN09951A (enExample) |
| MX (2) | MX2014014290A (enExample) |
| WO (1) | WO2013177264A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2014268316B2 (en) | 2013-05-23 | 2019-10-10 | Takeda Pharmaceutical Company Limited | Anti-CCL2 and anti-LOXL2 combination therapy for treatment of scleroderma |
| SI3094353T1 (sl) | 2014-01-15 | 2020-07-31 | Medimmune, Llc | RSY-specifična protitelesa in njihovi funkcionalni deli |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1272647T3 (en) * | 2000-04-11 | 2014-12-15 | Genentech Inc | Multivalent antibodies and uses thereof |
| EP1461300B1 (en) * | 2001-11-30 | 2011-07-27 | Biogen Idec MA Inc. | Antibodies against monocyte chemotactic proteins |
| CN1658895A (zh) * | 2002-04-10 | 2005-08-24 | 应用研究系统Ars股份公司 | 护骨素在治疗和／或预防纤维变性疾病中的应用 |
| US8114964B2 (en) * | 2005-05-19 | 2012-02-14 | Centocor, Inc. | Anti-MCP-1 antibodies, compositions, methods and uses |
| PA8675801A1 (es) * | 2005-05-19 | 2006-12-07 | Centocor Inc | Anticuerpos anti-mcp-1, composiciones, metodos y usos |
| US20080076120A1 (en) * | 2006-09-14 | 2008-03-27 | Millennium Pharmaceuticals, Inc. | Methods for the identification, evaluation and treatment of patients having CC-Chemokine receptor 2 (CCR-2) mediated disorders |
| AU2007319660A1 (en) * | 2006-10-05 | 2008-05-22 | Centocor Ortho Biotech Inc. | CCR2 antagonists for treatment of fibrosis |
-
2013
- 2013-05-22 IN IN9951DEN2014 patent/IN2014DN09951A/en unknown
- 2013-05-22 US US14/403,025 patent/US20150158942A1/en not_active Abandoned
- 2013-05-22 WO PCT/US2013/042196 patent/WO2013177264A1/en not_active Ceased
- 2013-05-22 AU AU2013266340A patent/AU2013266340A1/en not_active Abandoned
- 2013-05-22 HK HK15109600.6A patent/HK1208819A1/xx unknown
- 2013-05-22 EP EP13794678.6A patent/EP2852411A4/en not_active Ceased
- 2013-05-22 MX MX2014014290A patent/MX2014014290A/es unknown
- 2013-05-22 CN CN201610204124.0A patent/CN105854015A/zh active Pending
- 2013-05-22 EA EA201491957A patent/EA201491957A1/ru unknown
- 2013-05-22 JP JP2015514149A patent/JP2015520768A/ja active Pending
- 2013-05-22 BR BR112014029013A patent/BR112014029013A2/pt not_active Application Discontinuation
- 2013-05-22 CA CA2874031A patent/CA2874031A1/en not_active Abandoned
- 2013-05-22 CN CN201380038785.5A patent/CN104487091A/zh active Pending
- 2013-05-22 HK HK15109636.4A patent/HK1208825A1/xx unknown
-
2014
- 2014-11-21 MX MX2019006676A patent/MX2019006676A/es unknown
-
2016
- 2016-01-29 US US15/010,900 patent/US20160289319A1/en not_active Abandoned
-
2017
- 2017-08-04 JP JP2017151434A patent/JP2017193588A/ja active Pending
- 2017-09-12 US US15/702,206 patent/US20180179275A1/en not_active Abandoned
-
2018
- 2018-02-05 AU AU2018200834A patent/AU2018200834A1/en not_active Abandoned